Mesoblast Limited (NASDAQ:MESO) has been given a $16.00 price objective by investment analysts at Oppenheimer Holdings, Inc. in a research note issued on Tuesday. The firm presently has a “buy” rating on the stock. Oppenheimer Holdings, Inc.’s price target would indicate a potential upside of 196.30% from the company’s current price.
Several other research firms have also recently commented on MESO. BidaskClub cut Mesoblast Limited from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Maxim Group set a $14.00 target price on Mesoblast Limited and gave the company a “buy” rating in a research note on Wednesday, August 16th. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 target price on shares of Mesoblast Limited in a research note on Wednesday, August 30th. ValuEngine cut Mesoblast Limited from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Finally, CIBC began coverage on Mesoblast Limited in a research report on Thursday, August 31st. They issued an “outperform” rating and a $16.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $13.14.
Shares of Mesoblast Limited (MESO) opened at $5.40 on Tuesday. Mesoblast Limited has a 52 week low of $4.39 and a 52 week high of $12.50.
ILLEGAL ACTIVITY NOTICE: This report was reported by Stock Observer and is the property of of Stock Observer. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.thestockobserver.com/2017/11/15/oppenheimer-holdings-inc-reiterates-16-00-price-target-for-mesoblast-limited-meso.html.
About Mesoblast Limited
Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.